RA Capital Management’s Verona Pharma VRNA Stock Holding History

RA Capital Management’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,766,830	Closed	-$82.1M	–	98
2024 Q4	$82.1M	Sell	1,766,830 -3,242,823	-65%	-$122M	1.09%	23
2024 Q3	$144M	Sell	5,009,653 -2,622,993	-34%	-$64.6M	1.66%	20
2024 Q2	$110M	Buy	7,632,646 +1,314,656	+21%	+$19.2M	1.46%	19
2024 Q1	$102M	Hold	6,317,990	–	–	1.29%	24
2023 Q4	$126M	Hold	6,317,990	–	–	1.96%	12
2023 Q3	$103M	Hold	6,317,990	–	–	2.03%	10
2023 Q2	$134M	Hold	6,317,990	–	–	2.52%	8
2023 Q1	$127M	Hold	6,317,990	–	–	2.87%	7
2022 Q4	$165M	Buy	6,317,990 +267,990	+4%	+$3.57M	3.35%	5
2022 Q3	$61.8M	Buy	6,050,000 +950,000	+19%	+$8.01M	1.32%	26
2022 Q2	$21.4M	Hold	5,100,000	–	–	0.57%	44
2022 Q1	$25.4M	Hold	5,100,000	–	–	0.56%	50
2021 Q4	$34.3M	Hold	5,100,000	–	–	0.6%	49
2021 Q3	$27.9M	Hold	5,100,000	–	–	0.39%	55
2021 Q2	$33.4M	Hold	5,100,000	–	–	0.54%	53
2021 Q1	$42.6M	Hold	5,100,000	–	–	0.64%	44
2020 Q4	$31.8M	Hold	5,100,000	–	–	0.44%	51
2020 Q3	$31.8M	Buy	+5,100,000	New	+$35.2M	0.58%	42

Other funds holding VRNA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RA Capital Management's VRNA Position: Q1 2025 in Review

RA Capital Management sold out of Verona Pharma (VRNA) in Q1 2025, closing a stake of 1,766,830 shares — an estimated $82.1M sold.

RA Capital Management first reported a position in VRNA in Q3 2020 and held it in 18 quarters. The position peaked at $165M in Q4 2022. 258 funds tracked by Wall St. Rank hold VRNA as of Q1 2025.

RA Capital Management reported no remaining Verona Pharma position as of Q1 2025 after selling out during the quarter.
RA Capital Management sold 1,766,830 Verona Pharma shares in Q1 2025, an estimated $82.1M.
RA Capital Management first reported a position in Verona Pharma in Q3 2020 and held it in 18 quarters.
RA Capital Management's Verona Pharma position peaked at $165M in Q4 2022.
258 funds tracked by Wall St. Rank held Verona Pharma as of Q1 2025.

Based on RA Capital Management's 13F filing for Q1 2025, filed 15 May 2025.